ArticleFrontiers in public health2023

Cost-effectiveness analysis of durvalumab plus chemotherapy as first-line treatment for biliary tract cancer.

Zhuo-Miao Ye et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.